Antenatal magnesium sulphate reduces cerebral palsy after preterm birth, implementation into clinical practice needs to be accelerated globally to benefit preterm babies
Karen Luyt
DOI: https://doi.org/10.1002/14651858.ed000168
IF: 8.4
2024-09-25
Cochrane Database of Systematic Reviews
Abstract:In high‐income countries, 1.5 per 1000 live births are affected by perinatally acquired cerebral palsy, with a markedly higher birth prevalence in low‐ and middle‐income countries [1]. Preterm birth is a major cause of cerebral palsy; prevalence is negatively correlated with gestational age. At gestations of over 37 weeks, 32 to 36 weeks, 28 to 31 weeks and under 28 weeks, cerebral palsy prevalence is respectively 1.2 per 1000, 4.2 per 1000, 32.4 per 1000 and 70.6 per 1000 live births [2]. The first women were enrolled in trials that evaluated magnesium sulphate for fetal neuroprotection from 1995, and the first Cochrane review, published in 2009, concluded that antenatal magnesium sulphate therapy given to women at risk of preterm birth substantially reduced their child's risk of cerebral palsy [3]. Many professional bodies in high‐income countries subsequently adopted clinical practice guidelines [4]. In 2015. the World Health Organization (WHO) strongly recommended magnesium sulphate for women at risk of imminent preterm birth before 32 weeks' gestation for prevention of cerebral palsy [5]. A meta‐analysis of individual participant data demonstrated that in subgroup analysis the number needed to treat to prevent one case of cerebral palsy was 31 at gestations of under 28 weeks, 66 at 28 to 31 weeks and 90 at over 32 weeks [6]. Magnesium sulphate use for fetal neuroprotection below 30 weeks' gestation increased between 2012 and 2017 from 46% to 63% in the global Vermont Oxford Network (VON) [7]. The recently updated Cochrane review includes data from six randomized controlled trials (RCTs), and includes outcomes for 5917 women and 6759 babies at less than 34 weeks' gestation [8]. Magnesium sulphate administration and dosing regimens, and upper gestational limits varied between RCTs. The overall risk of bias was low. Certainty of evidence ranged from high to very low, due to varied concerns regarding quality, imprecision, and inconsistency. Key findings were that, up to two years' corrected age, magnesium sulphate compared with placebo reduced the relative risks for cerebral palsy (risk ratio (RR) 0.71, 95% confidence interval (CI) 0.57 to 0.89) as well as death or cerebral palsy (RR 0.87, 95% CI 0.77 to 0.98), both high‐certainty evidence. Magnesium sulphate compared to placebo resulted in little or no difference in fetal, neonatal or later death (RR 0.96, 95% CI 0.82 to 1.13). Magnesium sulphate compared with placebo may have resulted in little to no difference in death up to school age, death or cerebral palsy up to school age and cerebral palsy at school age, however the two trials that reported school‐age outcomes suffered attrition and statistical power limitations due to significant loss to follow‐up. Magnesium sulphate did not increase the risk of serious maternal complications (death, cardiac arrest, respiratory arrest), but probably increased adverse effects severe enough to stop treatment. These findings are consistent with the previous version of the Cochrane review [3], and support the WHO recommendation of magnesium sulphate for women at risk of imminent preterm birth worldwide [5]. The trials included in the Cochrane review were undertaken in hospital settings with access to intensive care and other essential supportive treatments for preterm infants. In these settings, magnesium sulphate for fetal neuroprotection is effective. Scale‐up to address remaining gaps in coverage should be a matter of priority. An exemplar national programme providing resources and local support for implementation was both effective and cost‐effective [9]. The International Federation of Gynecology and Obstetrics has recently launched a preterm optimisation care bundle, including magnesium sulphate, for middle‐resource settings [10]. Whether similar benefits are replicable in low‐resource settings, where the burden of preterm births is higher and access to neonatal intensive care is limited, remains to be demonstrated, and several new RCTs are recruiting in these settings. There were limitations in the subgroup and stratified analyses performed in the review. Subgroup analyses for primary outcomes (based on gestational age at randomization, loading dose regimen, maintenance dose regimen, and whether repeat treatment was permitted) revealed no clear differential treatment effects according to the characteristics assessed. The review could not assess the impact of the primary reason women were considered at high risk of preterm birth, number of babies in utero, mode of magnesium sulphate administration, and time treatment was intended to be started prior to preterm birth, due to paucity of or lack of stratified information and data. With the availability of individual participant data, the meta‐analyses would be able to assess the impacts of characteristics, such as the reason women were at risk of preterm birth, and total dose received by women, which were not -Abstract Truncated-
medicine, general & internal